Anadis goes over
Friday, 06 June, 2008
Victorian biotech Anadis (ASX: ANX) has sold over $820,000 worth of new shares to its shareholders under its share purchase plan (SPP), raising over $70,000 more than was intended.
The company, which specialises in polyclonal antibodies, said it had originally only intended to raise $750,000 under the SPP, but because of overwhelming interest decided to sell more, raising $823,000.
The new funds will be used to help fund clinical trials, and ultimately commercialise new products, the company said.
Diabetes changes the structure of our hearts, study finds
Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
